SG11202101779RA - Multi-chain chimeric polypeptides and uses thereof - Google Patents

Multi-chain chimeric polypeptides and uses thereof

Info

Publication number
SG11202101779RA
SG11202101779RA SG11202101779RA SG11202101779RA SG11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA SG 11202101779R A SG11202101779R A SG 11202101779RA
Authority
SG
Singapore
Prior art keywords
chimeric polypeptides
chain chimeric
chain
polypeptides
chimeric
Prior art date
Application number
SG11202101779RA
Other languages
English (en)
Inventor
Hing Wong
Original Assignee
Hcw Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hcw Biologics Inc filed Critical Hcw Biologics Inc
Publication of SG11202101779RA publication Critical patent/SG11202101779RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
SG11202101779RA 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof SG11202101779RA (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862725010P 2018-08-30 2018-08-30
US201862725043P 2018-08-30 2018-08-30
US201862724969P 2018-08-30 2018-08-30
US201862746832P 2018-10-17 2018-10-17
US201862749007P 2018-10-22 2018-10-22
US201862749506P 2018-10-23 2018-10-23
US201962816683P 2019-03-11 2019-03-11
US201962817230P 2019-03-12 2019-03-12
US201962817241P 2019-03-12 2019-03-12
US201962881088P 2019-07-31 2019-07-31
PCT/US2019/048881 WO2020047299A1 (en) 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
SG11202101779RA true SG11202101779RA (en) 2021-03-30

Family

ID=67928938

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101779RA SG11202101779RA (en) 2018-08-30 2019-08-29 Multi-chain chimeric polypeptides and uses thereof

Country Status (11)

Country Link
US (8) US11518792B2 (ja)
EP (1) EP3844181A1 (ja)
JP (2) JP7397874B2 (ja)
KR (1) KR20210070287A (ja)
CN (1) CN112996805A (ja)
AU (1) AU2019328290A1 (ja)
CA (1) CA3108949A1 (ja)
IL (1) IL280918A (ja)
SG (1) SG11202101779RA (ja)
TW (1) TW202122416A (ja)
WO (1) WO2020047299A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019328575A1 (en) 2018-08-30 2021-02-25 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
CA3108951A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
EP4321530A3 (en) 2018-09-27 2024-05-22 Xilio Development, Inc. Masked cytokine polypeptides
WO2020257639A1 (en) * 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021163299A1 (en) * 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
CA3184756A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
USD986799S1 (en) * 2020-09-11 2023-05-23 Wind Craft Aviation Inc. Aircraft
CN114042154A (zh) * 2021-12-14 2022-02-15 澳门大学 一种药物组合在制备抗肿瘤的联合治疗药物中的应用
WO2023134716A1 (zh) * 2022-01-14 2023-07-20 盛禾(中国)生物制药有限公司 一种结合b7h3和nkp30的双特异性抗体及其应用
WO2023168363A1 (en) * 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
US20240075141A1 (en) 2022-03-18 2024-03-07 WUGEN, Inc. Chimeric receptor constructs for nk cells
WO2023183853A1 (en) 2022-03-22 2023-09-28 WUGEN, Inc. Hybrid promoters, vectors containing same and methods of use
CN117924505A (zh) * 2024-03-25 2024-04-26 青岛宝迈得生物科技有限公司 一种重组hdac2蛋白单克隆抗体及其应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
DE69519929T2 (de) 1994-07-11 2001-05-23 Univ Texas Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
WO2001045636A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Pharmaceutical kit
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2002051871A2 (fr) 2000-12-26 2002-07-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticorps anti-cd28
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003104425A2 (en) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
NZ596825A (en) * 2002-07-15 2013-06-28 Univ Texas Duramycin peptides and their use in imaging
AU2003261787B2 (en) 2002-08-30 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
EP1599502A1 (en) 2003-02-27 2005-11-30 TheraVision GmbH A molecule which binds cd80 and cd86
MXPA05010035A (es) 2003-03-21 2005-11-17 Wyeth Corp Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
EP1631588A2 (en) 2003-05-23 2006-03-08 Wyeth Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
EP1730194B1 (en) 2004-03-30 2011-11-02 Yissum Research Development Company of the Hebrew University of Jerusalem Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
KR101203328B1 (ko) 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
ATE459648T1 (de) 2005-05-11 2010-03-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
ES2456296T3 (es) 2008-03-27 2014-04-21 Zymogenetics, Inc. Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
DK2307454T3 (en) 2008-06-25 2017-04-24 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies that inhibit VEGF
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
TW201119673A (en) 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
PE20121531A1 (es) 2009-10-15 2012-12-22 Abbott Lab Inmunoglobulinas con dominio variable dual
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2534178A4 (en) 2010-02-11 2013-08-07 Alexion Pharma Inc THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
CN102939305B (zh) 2010-04-08 2016-08-17 Jn生物科学有限责任公司 对cd122的抗体
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
WO2012051147A1 (en) 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
CN102153653B (zh) 2010-12-30 2012-08-15 厦门大学 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
KR101517320B1 (ko) 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
LT2703486T (lt) 2011-04-25 2018-05-25 Daiichi Sankyo Company, Limited Anti-b7-h3 antikūnas
KR102046666B1 (ko) 2011-05-25 2019-11-19 이나뜨 파르마 염증성 장애의 치료를 위한 항-kir 항체
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
US9403911B2 (en) 2011-06-06 2016-08-02 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
CA2839480A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
WO2013112923A1 (en) 2012-01-26 2013-08-01 Nugen Technologies, Inc. Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
CA2879494A1 (en) 2012-08-28 2014-03-06 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
MX358321B (es) 2012-11-20 2018-08-14 Sanofi Sa Anticuerpos anti-ceacam5 y usos de los mismos.
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
EP2958942B1 (en) 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
CN103709251B (zh) 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
IL250583B (en) 2014-08-19 2022-07-01 Merck Sharp & Dohme Anti-tigit antibodies
HUE047806T2 (hu) 2014-08-29 2020-05-28 Hoffmann La Roche Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel
WO2016106221A1 (en) 2014-12-22 2016-06-30 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
BR112017022255A2 (pt) 2015-04-17 2018-08-28 Centre Nat Rech Scient anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
KR101778439B1 (ko) 2015-04-27 2017-09-14 울산대학교 산학협력단 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물
CA2994906A1 (en) 2015-08-06 2017-02-09 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies
EP3348276B1 (en) 2015-09-11 2021-07-14 Y'S AC Co., Ltd. Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
WO2017053748A2 (en) 2015-09-25 2017-03-30 Genentech, Inc. Anti-tigit antibodies and methods of use
US10865232B2 (en) 2015-11-13 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-IG fusion protein for cancer immunotherapy
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
WO2017189526A1 (en) 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
KR20190091264A (ko) 2016-10-21 2019-08-05 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
US20210230221A1 (en) 2017-01-03 2021-07-29 Bioatla, Llc Protein therapeutics for treatment of senescent cells
KR20190120276A (ko) 2017-02-28 2019-10-23 아피메트 게엠베하 항―ｃｄ１６ａ 항체와 사이토카인의 조합물
CA3216726A1 (en) 2017-03-06 2018-09-13 Altor Bioscience Corporation Il-15-based fusions to il-12 and il-18
KR20190126182A (ko) 2017-03-27 2019-11-08 난트셀, 인크. aNK 및 IL-12 조성물 및 방법 (ANK AND IL-12 COMPOSITIONS AND METHODS)
AU2018323455B2 (en) 2017-08-28 2022-02-03 Altor Bioscience Llc IL-15-based fusions to IL-7 and IL-21
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3108951A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
AU2019328575A1 (en) 2018-08-30 2021-02-25 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
US20210338724A1 (en) 2020-02-11 2021-11-04 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
JP2023519107A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド 制御性ｔ細胞を活性化する方法
US20220073578A1 (en) 2020-06-01 2022-03-10 HCW Biologics, Inc. Methods of treating aging-related disorders

Also Published As

Publication number Publication date
US11518792B2 (en) 2022-12-06
US20230272027A1 (en) 2023-08-31
US11884712B2 (en) 2024-01-30
US20240124544A1 (en) 2024-04-18
WO2020047299A1 (en) 2020-03-05
US20240132561A1 (en) 2024-04-25
JP2021534828A (ja) 2021-12-16
US20240124543A1 (en) 2024-04-18
US20210070826A1 (en) 2021-03-11
CN112996805A (zh) 2021-06-18
CA3108949A1 (en) 2020-03-05
US20200071374A1 (en) 2020-03-05
IL280918A (en) 2021-04-29
EP3844181A1 (en) 2021-07-07
TW202122416A (zh) 2021-06-16
AU2019328290A1 (en) 2021-02-25
KR20210070287A (ko) 2021-06-14
JP7397874B2 (ja) 2023-12-13
US20230128292A1 (en) 2023-04-27
JP2024026248A (ja) 2024-02-28
US20210070825A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
IL280918A (en) Multichain chimeric polypeptides and their uses
IL280920A (en) Single-chain and multi-chain chimeric polypeptides and their uses
IL273327A (en) Chimeric polypeptides and their uses
IL281776A (en) Masked cytokine polypeptides
IL280915A (en) Single chain chimeric polypeptides and uses thereof
IL279505A (en) Chimeric transmembrane protein and its uses
SG11202106257WA (en) Chimeric receptor polypeptides and uses thereof
IL287781A (en) Clec-12a binding polypeptides and uses thereof
IL280808A (en) OX40-binding polypeptides and their uses
IL287782A (en) 33cd-binding polypeptides and their uses
ZA201906235B (en) Csf1r-based chimeric proteins
IL281088A (en) FLT3L - based chimeric proteins
IL289122A (en) polypeptides
GB201819200D0 (en) Polypeptide and uses thereof
GB201707139D0 (en) Polypeptides
IL289119A (en) polypeptides
IL281762A (en) Arginase proteins1
GB201719557D0 (en) Polypeptide
IL268170A (en) vsig8-based chimeric proteins
EP3830105A4 (en) CHIMERIC IMMUNOGENIC POLYPEPTIDES
GB201820556D0 (en) Novel polypeptides
GB201810052D0 (en) Polypeptide
GB201906126D0 (en) Chimeric protein
GB201811755D0 (en) Polypeptides
GB201807890D0 (en) Polypeptides